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hedding Light on High-Density
ipoprotein Cholesterol
he Post-ILLUMINATE Era*
arl J. Lavie, MD, FACC,
ichard V. Milani, MD, FACC
ew Orleans, Louisiana
lthough age-adjusted mortality rates from coronary heart
isease (CHD) have decreased by nearly 70% during the
ast half-century, cardiovascular disease still remains the
umber one killer in the U.S. (1). During this time period,
umerous public health efforts, pharmacologic advances,
nd interventional strategies have contributed to the dra-
atic decline in CHD. In the past 20 years, substantial lipid
ntervention directed at lowering levels of low-density li-
oprotein cholesterol (LDL-C) with a statin medication has
ontributed to the decline in CHD events (2). Continued
dvancements against CHD, however, will likely require
herapeutic targets beyond LDL-C (3).
pidemiologic Evidence
uring the last several years, substantial enthusiasm has
een directed toward the importance of low levels of
igh-density lipoprotein cholesterol (HDL-C), particularly
egarding the potential for aggressive pharmacologic eleva-
ion (4). Certainly, epidemiologic evidence has supported a
owerful inverse relationship between levels of HDL-C and
HD events. Based on data from the Framingham Heart
tudy, the risk of major CHD events increased by nearly
See page 49
5% for every 5-mg/dl decrease in HDL-C below the
edian values (5). In a meta-analysis of 4 large population-
ased studies, every 1% increase in HDL-C corresponded to
nearly 3% reduction in CHD risk (6). In epidemiologic
tudies, including Framingham, CHD events have corre-
ated more strongly with HDL-C than with either total or
DL-C levels. These data are particularly relevant, because
ow levels of HDL-C are present in over one-fourth of
dults and over one-half of patients with CHD in the U.S.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thea
merican College of Cardiology.
From the Ochsner Medical Center, New Orleans, Louisiana.4,7,8). Although lowering LDL-C, typically with statins, is
ell established to reduce major CHD events, several trials
hat demonstrated particularly marked CHD event reduc-
ion were associated with more significant HDL-C raising
9,12).
echanisms of HDL-C
lthough much of the antiatherosclerotic properties of
DL-C is considered to be mediated by reverse cholesterol
ransport (RCT), a process in which excess cholesterol in
ells and, particularly, atherosclerotic plaque is removed,
DL-C has other beneficial effects, including reducing
ndothelial dysfunction, as well as antiinflammatory, anti-
xidant, and antithrombotic effects (13,14). Despite these
otential theoretical benefits and the substantial epidemio-
ogic and limited pharmacologic data that would support
linical event reduction with HDL-C raising interventions,
everal trials with fibrates (15–17), estrogens (18,19), and,
articularly, cholesterol ester transport protein (CETP)
nhibition with torcetrapib (20) have demonstrated neutral
ffects or even harm related to HDL-C–elevating inter-
entions. Disappointment in HDL-C intervention
eached its pinnacle when the major morbidity and
ortality trial, ILLUMINATE (Investigation of Lipid
evel Management to Understand Its Impact in Athero-
clerotic Events), was halted owing to excess mortality in
he torcetrapib group (20).
he CETP Inhibition “Bust”
espite substantial enthusiasm directed toward CETP in-
ibition and the first agent in its class, torcetrapib, the
ailure of this agent to reduce CHD events and possibly
ause harm were partly predictable (4,13). Although a
ossible contributing factor to torcetrapib’s downfall was
hat it increased blood pressure in some patients, its major
ailure was likely due to producing HDL-C elevation without
CT augmentation (4,20). In fact, subsequent to the termi-
ation of all torcetrapib trials after ILLUMINATE, results of
major trials were published showing no significant effects of
his therapy on coronary or carotid atherosclerosis progression
espite marked increases in HDL-C (21,22). Although
hese data have resulted in the “death” of torcetrapib and
essimism toward the entire field of CETP inhibition, it
hould be noted that the relationship among CETP levels,
ETP polymorphism, HDL-C concentrations and activity,
nd CHD appears to be complex and certainly additional
esearch is needed.
hen Good Cholesterol Goes Bad?
lthough it is not clear if the negative data with torcetrapib
as due to CETP inhibition in general or adverse effects of
he particular agent used, likely both the blood pressure
ncreases and production of an “inactive” HDL that lacks
ignificant RCT contributed to the poor results with this
gent (4,20). Complicating the clinical relevance of raising
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January 1/8, 2008:56–8 Editorial CommentDL-C is the recent suggestion that in systemic inflam-
atory states, including acute coronary syndrome (ACS),
DL-C may convert from anti-inflammatory to proinflam-
atory (23–27). Augmenting the inflammatory response
ay be beneficial in connective tissue diseases and combat-
ng infection, but in atherosclerotic disease such as ACS,
his effect is likely detrimental (26,27). It has been suggested
hat HDL-C normally supports an anti-inflammatory state,
ut in the acute inflammatory environment, as in ACS,
DL’s antioxidant enzymes are inactivated and accumulate
levated levels of oxidized lipids, making HDL-C proin-
ammatory (25–27). Therefore, HDL-C may actually lower
HD risk in chronic atherosclerosis but possibly potentiate
isk in the setting of ACS. Although this concept deserves
urther study, clinical trials with other HDL-raising thera-
ies (i.e., niacin, exercise) have not demonstrated clinical
arm, including an increase in CHD death or ACS events.
resent Study
n this issue of the Journal, a large Veterans Administration
tudy by deGoma et al. (28) demonstrated a strong inverse
elationship between HDL-C and CHD risk even among
atients with very low levels of LDL-C 60 mg/dl (mean
50 mg/dl). In fact, in these patients with very low levels of
DL-C (well below the aggressive “optional” guidelines),
very 10-mg/dl reduction in HDL-C was associated with a
0% increase in major CHD events. Other studies have also
upported this relationship. In 2 post-ACS pravastatin
tudies of 13,173 patients, low HDL-C was a significantly
tronger predictor of CHD events in patients with LDL-C
125 mg/dl compared with those with LDL-C 125
g/dl (29). For every 10-mg/dl increase in HDL-C with
ravastatin, CHD event rate decreased by 29% in those with
DL-C 125 mg/dl compared with only 10% reduction in
hose with LDL-C 125 mg/dl. In a recent large intensity
rial of low-dose (10 mg) versus high-dose (80 mg) atorva-
tatin in patients with stable CHD, HDL-C remained a
otent predictor of CHD risk even in those who achieved
DL-C levels of 70 mg/dl (30). In fact, according to the
ramingham Heart Study, a patient with HDL-C of 25
g/dl and LDL-C of only 100 mg/dl has the same CHD
isk as does a patient with LDL-C of 220 mg/dl and
DL-C of 45 mg/dl (31).
The U-shaped relationship between HDL-C and all-
ause mortality in the current study may be slightly surpris-
ng, with those in the highest quartile of HDL-C having
igher mortality than those in the second and, especially,
hose in the third quartile; this effect was at least partly
xplained by alcohol abuse or dependence (suggesting that
his relationship may be partly an association and not
ecessarily causal) (28,32). As the authors mentioned (28),
revious epidemiologic studies from the U.S., Norway,
inland, and, especially, Russia noted a similar U-shaped
elationship between HDL-C and total mortality, including
eaths from excess alcohol, violence, or accidents. On thether hand, HDL-C levels above 75 mg/dl had been
ssociated with prolonged life (the “longevity syndrome”)
nd freedom from CHD events (33). In fact, in a review by
lueck et al. (33) of 18 kindred with functional hyper-
lphalipoproteinemia and very high levels of HDL-C, men
nd women lived 5 and 7 years longer, respectively, com-
ared with those in the general U.S. population.
onclusions
ased on the conflicting data that we currently have
egarding the risk of low HDL-C and therapies to increase
DL-C, how should clinicians and researchers proceed at
resent? As illustrated in the present report by deGoma
t al. (28) in the Veterans Administration study, low levels
f HDL-C are certainly potent predictors of CHD risk,
ven in the setting of quite low and desirable levels of
DL-C. We believe that HDL-C remains a viable target
or reduction of CHD, particularly when using proven
herapies (e.g., exercise training [34–36], weight reduction
36,37], moderate doses of alcohol [32], niacin [38–41],
nd certain fibrates [10–12,42]) that not only raise HDL-C
ut also stimulate RCT, translating into a reduction in
HD risk. At times, however, epidemiologic and preclinical
tudies (e.g., hormone replacement regimens, antioxidant
itamins, and so on), including that with a new and
reviously untested HDL-C intervention, torcetrapib (20),
ave not lived up to their promises and, in fact, have led us
stray. However, it should be emphasized that raising
DL-C by all other means has been shown to be safe and
ffective, and, as yet, the only exception has been CETP
nhibition. Therefore, we should not throw out the baby
ith the bath water. The “bust” with CETP inhibition (at
east with torcetrapib) does not mean that we should
bandon other HDL-C–elevating therapies. Nevertheless,
uture new classes of HDL-C therapies should focus on the
uality (especially that which stimulates RCT), not just the
uantity of HDL-C, and will require absolute proof of
enefit and safety from large-scale randomized, controlled
rials assessing CHD events, noncardiovascular morbidity
nd mortality, and all-cause mortality.
eprint requests and correspondence: Dr. Carl J. Lavie, Med-
cal Director, Cardiac Rehabilitation and Prevention, Director,
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